Zevra Therapeutics Inc’s filing revealed that its CFO & Treasurer Clifton R. LaDuane acquired Company’s shares for reported $13540.0 on Jul 17 ’24. In the deal valued at $6.77 per share,2,000 shares were bought. As a result of this transaction, Clifton R. LaDuane now holds 18,469 shares worth roughly $0.13 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Anderson Thomas bought 10,000 shares, generating $68,065 in total proceeds. Upon buying the shares at $6.81, the Director now owns 20,000 shares.
Before that, Bode John B bought 10,000 shares. Zevra Therapeutics Inc shares valued at $58,661 were divested by the Director at a price of $5.87 per share. As a result of the transaction, Bode John B now holds 30,000 shares, worth roughly $0.22 million.
Maxim Group reiterated its Zevra Therapeutics Inc [ZVRA] rating to a Buy in a research note published on September 24, 2024; the price target was $25. A number of analysts have revised their coverage, including JMP Securities’s analysts, who began to cover the stock in late September with a ‘”a Mkt outperform”‘ rating. Maxim Group also remained covering ZVRA and reiterated its “Buy” recommendation on April 02, 2024. William Blair started covering the stock on March 12, 2024. It rated ZVRA as “an Outperform”.
Price Performance Review of ZVRA
On Friday, Zevra Therapeutics Inc [NASDAQ:ZVRA] saw its stock jump 0.28% to $7.20. Over the last five days, the stock has gained 4.05%. Zevra Therapeutics Inc shares have risen nearly 9.92% since the year began. Nevertheless, the stocks have risen 56.52% over the past one year. While a 52-week high of $8.95 was reached on 09/20/24, a 52-week low of $3.89 was recorded on 07/05/24. SMA at 50 days reached $7.21, while 200 days put it at $5.88.
Levels Of Support And Resistance For ZVRA Stock
The 24-hour chart illustrates a support level at 7.04, which if violated will result in even more drops to 6.89. On the upside, there is a resistance level at 7.38. A further resistance level may holdings at 7.57. The Relative Strength Index (RSI) on the 14-day chart is 48.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.29, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 74.79%. Stochastics %K at 23.79% indicates the stock is a holding.
How much short interest is there in Zevra Therapeutics Inc?
A steep rise in short interest was recorded in Zevra Therapeutics Inc stocks on 2024-09-13, dropping by 59384.0 shares to a total of 3.77 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 3.82 million shares. There was a decline of -1.58%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 17, 2023 when Maxim Group began covering the stock and recommended ‘”a Buy”‘ rating along with a $12 price target.
